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Abstract Today, European biomedical and health-related
research is insufficiently well funded and is fragmented,
with no common vision, less-than-optimal sharing of resour-
ces, and inadequate support and training in clinical research.
Improvements to the competitiveness of European biomed-
ical research will depend on the creation of new infrastruc-
tures that must be dynamic and free of bureaucracy, involve
all stakeholders and facilitate faster delivery of new discov-
eries from bench to bedside. Taking diabetes research as the
model, a new paradigm for European biomedical research is
presented, which offers improved co-ordination and com-
mon resources that will benefit both academic and indus-
trial clinical research. This includes the creation of a
European Council for Health Research, first proposed
by the Alliance for Biomedical Research in Europe,
which will bring together and consult with all health
stakeholders to develop strategic and multidisciplinary
research programmes addressing the full innovation cycle.
A European Platform for Clinical Research in Diabetes is
proposed by the Alliance for European Diabetes Research
(EURADIA) in response to the special challenges and
opportunities presented by research across the European
region, with the need for common standards and shared
expertise and data.
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Europe is falling behind its traditional competitors in biomedi-
cal and health-related research, the USA and Japan, as well as
facing increasing competition from newly emerging countries
such as China. Lack of co-ordination, inadequate funding (rel-
ative to gross domestic product [GDP]) and the complexities
inherent in any activity across several countries, each with
different commitments and local regulatory constraints, have
combined to handicap the European biomedical research enter-
prise. Although research funding is notoriously difficult to
estimate precisely, evaluation by the Organisation for Economic
Co-operation and Development (OECD) for the years 2007–
2009 concluded that the average funding for research in the
USAwas around twice that of the European Union (EU) ($31
billion vs $17 billion per year) [1]. Despite repeated commit-
ments from the European Commission [2], European invest-
ment in research is still woefully short of the Commission’s own
target of 3% GDP, and much lower than in the USA or Japan
[3]. Best estimates for funds devoted exclusively to diabetes
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research in 2008 in the USA and Europe suggest a similar
disparity (USA $1,080 million [4]; Europe €323 million [5]).
Clinical research is obviously a key component of trans-
lational research, embracing all studies on living individuals
as well as safety and efficacy studies on new therapeutic
molecules. Despite the impressive history of clinical re-
search in Europe, with major contributions to our under-
standing of diseases and the development of innovative
therapeutic approaches for their treatment, the situation to-
day is worrisome. As always in times of financial constraint,
health and education, including research, will be among the
first to suffer from budget cuts. Indeed, at the time of writing
there is political uncertainty surrounding the budget for
Horizon 2020 (the EU Framework Programme for Research
and Innovation for the period 2014–2020) with the serious
risk of a substantial decrease in overall funding. National
funding of research will certainly also suffer in many Euro-
pean countries. We must therefore find new ways to make
biomedical research in general, and clinical research in
particular, not only more cost-effective but also more com-
petitive, offering more to society in return for investment,
while allowing equal access to high-quality clinical studies
for all citizens in Europe. Clinical research is undertaken
both by academia and the pharmaceutical industry, albeit
generally for different reasons. Faced with increasingly
challenging demands from regulatory agencies and the spi-
ralling costs of clinical studies, pharmaceutical companies
would also benefit greatly from any common infrastructure
that offered greater efficacy and improved co-ordination of
clinical research.
European Council for Health Research
Strategic planning across disciplines and involving all major
health stakeholders is required to enable the realisation of
the EU’s ‘Innovation Union’ initiative [6]. This aims to
create an environment in Europe that supports the trans-
lation of novel ideas into products and services, can
generate growth and jobs, and improve well-being. Bio-
medical research represents an outstanding example of
research-driven innovation that can promote future
growth.
For the first time, the European biomedical community
has come together as an ‘Alliance for Biomedical Research
in Europe’, which already represents 21 major health re-
search organisations and around 250,000 scientists
(www.biomedeurope.org/). The BioMed Alliance is calling
on EU and national decision-makers in Europe for urgent
action to help science achieve true innovation that can create
a healthier and more prosperous environment for Europe’s
citizens. The BioMed Alliance is forcefully promoting the
creation of the European Council for Health Research
(EuCHR), which can provide the best scientific leadership
to EU programmes in health research and will bring together
and consult with all health stakeholders. The overall goal is
to accelerate research in the biomedical field in Europe
through long-term strategic research programmes capable
of triggering multidisciplinary partnerships and addressing
the full innovation cycle. As shown in Fig. 1, translational
research (‘from bench to bedside’) involves three major
levels of research (Fig. 1, black), with multiple performance
sites (Fig. 1, red) and both public and private sources of
funding (Fig. 1, blue). The EuCHR would allow for co-
ordination of this complex enterprise that is presently miss-
ing in Europe, thereby speeding delivery of new drugs to
patients while making this more cost-effective. At the time
of writing the EuCHR is being discussed with the European
Commission Directorate General for Research and Innova-
tion and key members of the European Parliament. It is
hoped that this council can be established to coincide with
the Horizon 2020 programme.
Aims of the European Council for Health Research (EuCHR) 
• Accelerate excellent biomedical and health-related research in Europe  
• Seek better co-ordination and strategic planning of biomedical research funding programmes
• Define and support high-level research programmes in order to achieve translation and
innovative outcomes
• Promote deeper and longer-term collaborative initiatives that address current gaps in the 
innovation cycle
• Provide strategic advice on the steering of European health research to policy makers
• Incorporate all relevant stakeholders in order to boost creativity and innovation
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European Platform for Clinical Research in Diabetes
The DIAMAP project, a roadmap for European diabetes
research, was supported by a grant from the European
Commission Seventh Framework Programme (FP7) and
submitted its report in 2010 (full report and a summary
brochure at www.diamap.eu [7]). A major recommendation
was to create a European Platform for Clinical Research in
Diabetes (EPCRD). Although focused on a single disease,
the fact that diabetes, together with its macrovascular and
microvascular complications and comorbidities, is of com-
mon interest to most members of the BioMed Alliance
makes the concept and rationale for such a platform directly
in line with the major goals of the EuCHR; indeed, the
EPCRD was used as one of only a handful of examples in
support of the BioMed Alliance’s White Paper on the crea-
tion of the EuCHR. The Alliance for European Diabetes
Research (EURADIA; www.euradia.org), the coordinator of
DIAMAP, intends to promote the development of the
EPCRD.
Rationale The DIAMAP road maps repeatedly mentioned
as roadblocks the need for registries of people with diabetes,
networks of specialist researchers, access to biobanks and
human biological material (especially in relation to the rarer
complications) and more standardised evidence-based treat-
ment guidelines. Lack of political and public understanding
of biomedical research and its importance to society was
also cited as a roadblock, with the recommendation for
better education leading to greater involvement of people
with diabetes in clinical research; their support is essential
and offers a significant opportunity for transparency in
determining how diabetes research budgets are spent. The
EPCRD will for the first time in Europe offer equal access to
clinical research to all people with diabetes, across all tra-
ditional borders of language, culture and education. It was
Fig. 1 European translational research landscape. This scheme indi-
cates the current complexity and fragmentation of European biomedi-
cal research, with multiple public and private stakeholders operating
independently. Major entities performing research are shown in red, the
level (or stage) of research in black, and funding sources in blue.
European Commission funding would include the current FP7 and
the future Horizon 2020 programme supported by the Directorate
General for Research and Innovation. Private support is from industry
or SMEs (small and medium enterprises). Specific examples of funding
sources are provided for illustrative purposes only and should not be
considered exhaustive. Coordinating structures described further in the
text are shown in green. The EuCHR proposed by the BioMed Alliance
is intended to coordinate all biomedical research activities in Europe.
Clinical research platforms, such as the EPCRD under development by
EURADIA, would offer the public and private sectors improved effi-
cacy and competitiveness. ERC, European Research Council; IMI,
Innovative Medicines Initiative; NGO, non-governmental organisation
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further felt that diabetes research would be enhanced if the
clinical research community itself could drive a collabora-
tive initiative as it deals with the consequences of research
on treatment and care delivery. EURADIA is hoping to
create the platform in 2013 and will support a research
project to test the system before it is made available to all
stakeholders as a fully integrated component of a new land-
scape for European clinical research (Fig. 1).
Conclusions
There is an urgent need for an umbrella organisation to oversee
and coordinate biomedical and health-related research in
Europe. This organisation would ideally be independent of
European and national funding agencies but supported by them
and fully integrated into a truly regional research operation. We
believe that the EuCHR, as proposed by the BioMed Alliance,
would satisfy all these requirements, offering in return to the
European Commission, national governments and most impor-
tantly the citizens of Europe, a healthier future thanks to more
effective translational research and improved return on
investment for society at large, with more jobs and
greater innovation. The proposed EPCRD would be just
one activity of the EuCHR among many others, serving
as a model for all disease areas.
This new paradigm for biomedical research in Europe,
taking diabetes as the model case, will only become a reality
if it receives proactive support from all stakeholders. Research-
ers, health professionals, private enterprises, non-governmental
organisations and, last but by no means least, people with
diabetes and their families, should advocate at the local, nation-
al and regional levels to ensure that there will be political and
budgetary support for the creation of the proposed infrastruc-
ture. The EASD, a founding member of both the BioMed
Alliance and of EURADIA, and its foundation (the EFSD),
the leading pan-European diabetes research funding agency, are
uniquely well placed to promote this bold new action plan.
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European Platform for Clinical Research in Diabetes (EPCRD)  
Aims
• Facilitate and enhance clinical diabetes research with the purpose of improving care and
treatment for people with diabetes  
Objectives 
• Create centrally determined governance structures in line with current ethical guidelines
Facilitate access to information and online databases of clinical studies and trials, thus 
encouraging participation by interested volunteers (with diabetes and without). The closer
dialogue between professionals and research participants is intended to encourage greater
understanding of the science  
Improve access to structured education and training for European diabetes researchers and
healthcare professionals engaging in research activity  
Improve access to information and structured education for people living with diabetes
Facilitate access to data and biological samples by providing a uniformly agreed and ethically
approved infrastructure to permit sample and data sharing across multiple national and
international security barriers 
Encourage investment by and participation of industry, facilitating access to a large number
of research subjects and to scientists from subspecialties. Funding of industry-initiated
trials could be standardised across Europe supporting the concept of the ‘European diabetes
patient’. The use of such a market approach to clinical research has the potential to drive
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